Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00924638 · ClinicalTrials.gov registry record · Phase 4
Study of Continuous Cardiac Monitoring to Assess Atrial Fibrillation After Cryptogenic Stroke
A Phase 4 study, sponsored by Medtronic Cardiac Rhythm and Heart Failure.
- Completed
- Registry status
- Phase 4
- Development phase
- 447
- Enrollment target
NCT00924638 is a Phase 4 study that has completed, run by Medtronic Cardiac Rhythm and Heart Failure. The registered enrollment target is 447 participants.
The verdict
NCT00924638, a Phase 4 study, has completed, sponsored by Medtronic Cardiac Rhythm and Heart Failure.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 447 participants
- Enrollment target
Study Summary
The 2006 American Heart Association / American Stroke Association Council on Stroke Guidelines for Prevention of Stroke in Patients With Ischemic Stroke or Transient Ischemic recommended that patients with cryptogenic stroke take antithrombotic drugs (i.e. aspirin) in order to prevent a second stroke. When a stroke patient is found to have atrial fibrillation (AF), the guidelines recommend oral anticoagulation due to its superior efficacy over aspirin for stroke prevention. Physicians can best optimize the use of medicines only if they can precisely and correctly diagnose a patient's AF. The purpose of this study is to evaluate the time to first AF by 6 months' continuous rhythm monitoring versus control treatment in subjects with a recent cryptogenic stroke or Transient Ischemic Attack (TIA) without history of AF.
Interventions
- DEVICE Reveal® XT Insertable Cardiac Monitor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 447 participants |
| Start Date | 2009-06 |
| Est. Completion | 2013-05 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00924638
The ClinicalTrials.gov registry entry for NCT00924638 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 447 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medtronic Cardiac Rhythm and Heart Failure, which has 115 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Reveal® XT Insertable Cardiac Monitor is the first listed.
NCT00924638 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00924638 about?
NCT00924638 is a clinical study titled "Study of Continuous Cardiac Monitoring to Assess Atrial Fibrillation After Cryptogenic Stroke". The 2006 American Heart Association / American Stroke Association Council on Stroke Guidelines for Prevention of Stroke in Patients With Ischemic Stroke or Transient Ischemic recommended that patients with cryptogenic stroke take antithrombotic drugs (i.e. aspirin) in order to prevent a second strok...
What is the current status of trial NCT00924638?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 447 participants. The study started on 2009-06. Estimated completion is 2013-05.
What interventions are being tested in trial NCT00924638?
The interventions under investigation include: Reveal® XT Insertable Cardiac Monitor (DEVICE).
Who is sponsoring clinical trial NCT00924638?
This trial is sponsored by Medtronic Cardiac Rhythm and Heart Failure, which has 115 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.